ImmunoHub.org – Immuno-Oncology Essentials – Home › Forums › Immunotherapy › Expectations for therapy › nivolumab › Reply To: nivolumab
October 3, 2017 at 6:55 pm
#4190
The prescribing information indicates until disease progression or unacceptable toxicity. The interpretation of these criteria varies from institution to institution and from provider to provider